A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. J of Skin [Internet]. 2019 Nov. 9 [cited 2026 Apr. 17];3:S18. Available from: https://skin.dermsquared.com/skin/article/view/745